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INTRODUCTION
The mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase and a member of the phosphatidylinositol-3-OH kinase (PI3K) family (Lamming et al., 2013; Johnson et al., 2013) . mTOR is active when associated with protein complexes that have differing functions and sensitivities to inhibition by rapamycin. mTOR complex 1 (mTORC1) is acutely sensitive to allosteric inhibitor rapamycin, while mTORC2 is acutely resistant, but ultimately, affected to some extent by chronic exposure to rapamycin. The biological functions of the mTOR complexes are to sense cellular availability of nutrients and other physiologically important signals such as amino acids, glucose, oxygen, WNT ligands, cAMP and insulin. As a result of these signals, mTORC1 activates translation and cell growth, while mTORC2 activates production of the cytoskeleton and phosphorylation of oncogenic AKT protein kinase. In particular, mTORC1 has been considered as a key modulator of several processes related to ageing and age-related disease. Indeed, inhibition of mTOR by rapamycin had been found to extend life span in a number of species, including mammals, with biological effects similar, but not necessarily identical, to those found following calorie/nutrient restriction (Lamming et al., 2013; Johnson et al., 2013; Fok et al., 2013) . The mechanism(s) behind extended life span are still under investigation, however, a number of possible mechanisms have been proposed, including anticancer effects, reduced translation, increased autophagy, support of functional stem cells, modulation of immune response, reduced inflammation and improved mitochondrial function.
While use of mTOR inhibitors as treatments for extending life span or for other age-related diseases in humans is still theoretical, rapamycin and analogs everolimus DMD #54809 and temsirolimus have been approved for use in the treatment of a limited number of cancers (Benjamin et al., 2011) . However, rapamycin and the analogs studied only incompletely inhibit mTORC1 phosphorylation, and selective inhibition of mTORC1 can increase AKT signaling by reducing negative feedback in the PI3K-mTORC2-AKT pathway. Therefore, second generation mTOR inhibitors, particularly ATP-competitive mTOR inhibitors that can more potently inhibit both mTORC1 and mTORC2, are being investigated for use in the oncology space, as well as to further elucidate the role of mTOR in ageing and disease (Benjamin et al., 2011; Schenone et al., 2011) .
Previously, Peterson et al. (2012) described the discovery of a series of selective imidazopyridazine mTOR inhibitors. In particular, compound 1 (Figure 1 ) IC50 against mTOR was found to be 13 nM, with 58x selectivity over PI3Kα. Compound 1 exhibited moderate clearance following an intravenous dose to rats (2.3 L/h/kg), and approximately 100% bioavailability following oral dose. Solubility and bioavailability were greatly improved with compound 1 as compared to its imidazopyridine analog.
Compound 1 shows promise as a tool for examining mTOR inhibition in vivo. However, little is known about the disposition of compound 1 across species. In the present study, the elimination of compound 1 is studied in bile duct cannulated rats and the metabolism of compound 1 in liver microsomes is compared across species.
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MATERIALS AND METHODS
Materials
Compound 1 (>98% purity) was synthesized by the Medicinal Chemistry department at Amgen, Inc (Cambridge, MA) (Peterson et al., 2012) . [ 14 C]-compound 1 (57.5 mci/mmol) was obtained from Moravek Biochemicals, Inc. (Brea, CA). All other compounds and reagents were obtained from commercial sources as appropriate.
Liver microsomes isolated from male Sprague-Dawley rats (n>100), pooled male beagle dogs (n=5), pooled male cynomolgus monkey (n=10) and pooled male and female human (n=50) were purchased from BD Biosciences (San Jose, CA). Recombinant c-DNA expressed human UGT isoforms UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B4, UGT2B7, UGT2B15 and UGT2B17 were obtained from BD Biosciences, San Jose, CA.
Excretion studies in bile duct catheterized (BDC) rats
All animal procedures were conducted under protocols approved by the Amgen (Cambridge) Institutional Animal Care and Use Committee. Three male SpragueDawley rats were purchased from Charles River Laboratories (Wilmington, MA). The rats were housed in a humidity-and temperature-controlled environment subject to a 12 h:12 h light:dark cycle and had access to water and a standard laboratory diet ad libitum. Following a one week acclimation period, rats had Silastic catheters implanted in the bile duct and proximal duodenum using aseptic surgical techniques. The externalized catheters were protected with a Covance infusion harness (Instech Solomon, Plymouth Meeting, PA) and connected to permit recirculation of bile. The
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BDC rats were placed in Nalge metabolism cages (Nalge Company, Rochester, NY) and given access to food and water ad libitum. The rats were fasted overnight prior to dosing; food was returned 2 h post-dose. On the second day post-surgery, the catheters were connected to a dual channel swivel (Instech Solomon, Plymouth Meeting, PA) for the collection of bile and the infusion of artificial bile (25 mM sodium taurocholate:150 mM NaCl:7 mM KCl, 2 mL/h) (Klaassen, 1974) . Each BDC rat was administered a single dose of [ 14 C]-compound 1 (5 mg/kg, 100 µCi/kg PO). Bile, feces, and urine samples were collected at specified intervals through 48 h post-dose into pre-weighed bottles. The volume of bile and urine was determined gravimetrically, assuming a density of 1 g/mL.
Isolation of N-glucuronides from in vitro Incubations.
Ten milligrams of compound 1 (100 uM) was incubated with rat, dog, or monkey liver microsomes (2 mg protein/mL) in phosphate buffer (0.1 M, pH 7.4), with 10 mM MgCl2, 5 mM uridine-5'-diphosphoglucuronic acid (UDPGA), and 50 µg alamethicin/mg microsomal protein, for 4 h, at 37°C. The incubation mixture was extracted using an OASIS reverse phase cartridge (Waters Corporation, Milford, MA). The acetonitrile wash was evaporated and the sample was re-dissolved in HPLC mobile phase and separated using the system described under LC-MS analysis of BDC and in vitro samples. The HPLC eluate was split 1/20 with one part going to the MS and the rest to a Gilson FC 204 fraction collector (Gilson, Inc., Middleton, WI). The fraction containing the isolated glucuronide was dried, re-dissolved in HPLC solvent and subjected to further purification using a new HPLC column. The purity of the final product was determined by LC/MS (>90% for M1 and M2, >80% for M3).
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Structural elucidation of N-glucuronide metabolites by NMR
All NMR spectra were acquired on a Bruker Avance II spectrometer system operating at a proton frequency of 600.13 MHz. The parent and isolated metabolites were dissolved in d6-DMSO and NMR data were collected in a 1.7 mm tubes using a Bruker 5 mm TCI cryo-probe. Proton and carbon assignments were made by using standard 1-D and 2-D pulse sequences. All NMR spectra were collected at a temperature of 26°C.
In vitro metabolism of compound 1
For the identification of glucuronide metabolites in liver microsomes, radiolabeled compound 1 (10 µM, 28 mCi/mmol) was incubated with rat, dog, monkey, and human liver microsomes (1 mg protein /mL) in phosphate buffer (0.1 M, pH 7.4), with 10 mM MgCl 2 and 50 µg alamethicin/mg microsomal protein, for 1 h, at 37°C, with and without 5 mM uridine-5'-diphosphoglucuronic acid (UDPGA). The reaction mixtures were quenched with an equal volume of acetonitrile and centrifuged at 16,000 g for 5 min. The LTQ-Orbitrap was equipped with an API2 source and Xcalibur version 2.0 software (Thermo Electron Corp., San Jose, CA). All mass spectra were acquired in the high resolution mode using 30,000 resolving power. Exact mass measurement was accomplished using external calibration. Electrospray ionization with positive ion detection was used. The source temperature was set at 250°C, and the ion spray voltage was held at 4.5 kV. Pooled rat bile (0-48 hr, 5 µL), pooled rat urine (0-48 hr, 100 µL), or in vitro samples were loaded onto a YMC-AQ C18-A column (Torrance, CA) 4.6 x 250 mm, 5 µm particle size, 120 Å pore size). The metabolites were separated using a gradient solvent system consisting of two components, solvent A (0.1% formic acid in water) and solvent B (0.1% formic acid in acetonitrile). The percentage of solvent B was held at 5% for 3 minutes, then was increased in a linear fashion from 5% to 30% B over 37 minutes, and from 30% to 95% B in the next 10 minutes. The flow rate was set at 1.0 mL/min and the column eluate was split 1:20, with one part channeled to the ion source and the rest to the flow scintillation analyzer (waste for nonradiolabeled samples or fraction collector for isolation). The MS/MS spectra were recorded by collision-induced dissociation (CID) of [M+H] + species.
LC-MS analysis of BDC and in vitro samples
Samples from compound 1 depletion and N-glucuronide formation kinetics studies were analyzed by multiple reaction monitoring on an LC-MS/MS system consisting of dual Shimadzu LC-10AD HPLC pumps and a DGU-14A degasser (Shimadzu, Columbia, MD), a CTC PAL autoinjector (Leap Technologies, Carrboro, NC), and an API4000 MS system, equipped with an electrospray ion source and operated by the Analyst software package (Applied Biosystems, Foster City, CA). The source temperature was set to 400°C, and the ion spray voltage was set to 4.5kV.
Chromatography was conducted on a YMC ODS-AQ (50 x 4.6mm, 5µm) analytical column with a 0.5 µm PEEK guard filter, using the mobile phase solvents A and B described above at a flow rate of 0.7 mL/min. The percentage of solvent B was increased in a linear fashion from 2% to 18% over 7 minutes, then from 18% to 90% in the next 0.5 minutes and held at 90% for the next 2 minutes, when it was then returned to 2%. The LC eluent was diverted from the ion source to waste for the first 3 minutes 
Modeling of N-glucuronide metabolite formation kinetics
In order to determine which kinetic model(s) to use, Eadie-Hofstee plots were created using the reaction velocity data from each metabolite in liver microsomes of each species. Based on the appearance of the data in this plot, one of the following 
where v is the reaction velocity, V max is the maximum reaction velocity, K m is the concentration required to achieve 50% of the maximum reaction velocity, and C is the concentration of compound 1 in the incubation. Metabolite formation where the EadieHofstee plot appeared bi-phasic were described by a two enzyme model (two-site), 
where the substrate inhibition is considered to occur against the low affinity enzyme.
Finally, non-Michaelis-Menten kinetics displaying cooperativity was described by,
where n is the Hill coefficient. collection. The NMR studies of the isolated glucuronide metabolites were conducted by dissolving the metabolites (~100 µg) in 50 µL of DMSO-d6 and placing the samples in a 1.7 mm tubes for data collection. The proton and carbon assignments were obtained from the 1D (1H) and 2D (g-DQCOSY, g-HSQCdept, gradient-heteronuclear multiple bond correlation (g-HMBC), rotating-frame Overhauser effect spectroscopy (ROESY)) spectra collected on the samples (Table 1 ). The NMR spectra are consistent with the structures shown in Figure 1 . Glucuronide 1 (M1) was attached to N2 of the pyrazole ring and demonstrated by connections in the g-HMBC spectrum between H1 and C3.
In the ROESY spectrum of glururonide 1, a cross-peak was observed between the anomeric proton H1 and the secondary amine labeled 6. The attachment of glucuronide 2 (M2) was verified by g-HMBC connections between H1 and C5. The 
Metabolism of compound 1 in liver microsomes
Experiments were conducted using rat, dog, monkey and human liver microsomes to investigate the similarity of metabolism of compound 1 across species.
Preliminary experiments in the presence of UDPGA revealed that all three Nglucuronides observed in BDC rats were formed from rat liver microsomes with similar relative abundances, M1 > M2 > M3 (Figure 4 ). This suggests that liver microsomes are a suitable enzyme source for investigating N-glucuronide formation from compound 1 in vitro. Looking across species, M1 and M2 were formed by liver microsomes from all species tested, albeit to different extents. Formation of M3 was detected in rat, dog and human, but not monkey, liver microsomes. No other glucuronides were detected with liver microsomes in vitro. At a concentration of 10 µM, formation of M1 was substantially greater than formation of M2 or M3 in dog and human liver microsomes.
However, M2 was the major metabolite in monkey liver microsomes. Experiments with liver microsomes fortified with NADPH indicated that compound 1 undergoes rapid oxidative metabolism in dog and monkey liver microsomes, while that in rat and human liver microsomes occurs more slowly (Table 2) .
Metabolite formation experiments were conducted in order to further characterize the apparent species dependence in N-glucuronide formation. Concentration dependence in formation kinetics was described by a number of different kinetic models, depending on the appearance of Eadie-Hofstee plots. M1 formation was most accurately described by two-enzyme kinetic models in rat, dog and human liver microsomes, indicating the M1 is most likely primarily formed by two major UGT isoforms, within each of these species ( Figure 5 ). In dog, a substrate inhibition effect considerable variation across the species tested (Table 3 ). M2 formation was most accurately described by single-enzyme kinetic models. Models for M2 formation in dog, monkey and human liver microsomes fit best when a substrate inhibition effect was included. Substrate inhibition was not required to fit the formation of M2 in rat liver microsomes. Values for V max and K m showed a 10-fold or greater variation across species. One site kinetic models were also fit to the formation of M3. In some cases (rat and dog liver microsomes) required a substrate inhibition effect. M3 was not detected in incubations with monkey liver microsomes.
Formation of N-glucuronides in human UGTs
M1 was formed principally by UGT1A1 and UGT1A9 (Figure 8 ). M1 was also formed to a minor extent in UGT1A3, UGT1A7 and UGT1A8. Both M2 and M3 were principally formed by UGT1A9. M2 was formed to a minor extent in UGT1A1 and UGT1A3. M3 was formed to a minor extent in UGT1A1, UGT1A3, UGT1A4 and UGT1A8. No glucuronides were detected in incubations with UGT1A6, UGT1A10, UGT2B4, UGT2B7, UGT2B15 and UGT2B17. In addition, no other glucuronides (besides M1 -M3) were observed in incubations with isolated human UGTs.
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DISCUSSION
The mTOR inhibitor compound 1 was extensively glucuronidated in rats.
Substantial quantities of N-glucuronides, but minimal parent (<5% of dose), were found in both urine and bile of BDC rats dosed orally with compound 1. Although compound 1 contains several possible locations for direct N-glucuronidation, glucuronidation was detected only on N1 and N2 of the pyrazole moiety as well as on the primary amine (N23). No glucuronidation was detected on the secondary amine (N6) or tertiary amines (N8, N10, N11, N17 or N19). In addition, other glucuronides species such as carbamoyl glucuronides (Schaefer, 2006) were not detected in rat bile or urine.
However, it cannot be ruled out that such glucuronides exist, perhaps in quantities that are below the detection limits of radiochemical or LC-MS detection. Interestingly, the relative abundance of the three N-glucuronides were similar between urine and feces, with M1 being the major metabolite in urine and bile, and M2 and M3 formed to a smaller, though significant, extent. Since minimal (≤10% of parent) N-glucuronides were detected in rat plasma following an oral dose of compound 1 (unpublished data), it is possible that the N-glucuronides found in urine were formed by UGT enzymes in the kidney, perhaps by the same enzymes responsible for their formation in the liver.
However, given the wide tissue expression of UGT mRNA and activity in rats, their formation by other extrahepatic tissues cannot be ruled out at this time (Shelby et al., 2003; Shiratani et al., 2008) . Since the total quantity of dose excreted in urine was minor relative to that in bile (10% versus 52%, respectively), and oxidative metabolism was also a minor pathway, further detailed investigation of compound 1 metabolism was focused on N-glucuronide formation in liver microsomes, particularly, given available documentation that species differences in N-glucuronidation of aromatic N-heterocycles can be highly compound dependent (Kaivosaari et al., 2011) .
When incubated in rat liver microsomes in the presence of UDPGA, Compound 1 formed the same three glucuronides found in vivo to similar proportions, M1>M2>M3
( Figure 4 ). This helped to established confidence that liver microsomes were a reasonable enzyme source for investigating N-glucuronidation of compound 1.
Qualitative and quantitative species differences were found in the metabolism of compound 1 by liver microsomes, as were there some similarities. Firstly, all three Nglucuronides were detected in liver microsomes from dogs and humans. However, while M1 and M2 were detected in liver microsomes from monkeys, M3 was not detected. No other N-glucuronides were detected in liver microsomes from all species tested.
Secondly, M3 was consistently the relatively minor metabolite of the three,
across three of the species tested (rat, dog and human), or undetected in monkey (Figure 4) . However, at low concentrations (10 µM or less), M1 was the major metabolite formed in rat, dog and human liver microsomes, while M2 was the major metabolite formed in monkey liver microsomes. This species selectivity found in monkeys is unique when compared to other recent examples of triazole and pyrazole Nglucuronidation. In the case of FYX-051, the ratios of N1-to N2-glucuronide formation in vivo were quite similar in dogs, monkey and humans (Nakazawa et al., 2006) . In the case of JNJ-10198409, the N1-glucuronide was prominently formed in both monkey and human liver microsomes, while the N2-glucuronide was not detected in either species (Yan et al., 2006) . The reasons for the unique species selectivity with compound 1 are and UGT1A1 in humans in vitro. UGT1A1 is more or less conserved across species given its important role in bilirubin metabolism (Bosma et al., 1994; King et al., 1996) .
However, species differences have been reported in activity of UGT1A9. Dog and rat apparently lack meaningful propofol glucuronidation activity and UGT1A9 is a pseudogene in rats (Soars et al., 2001; Shiratani et al., 2008) . In addition, monkey and human UGT1A9 orthologs were found to be 93% homologous, and structurally and functionally similar (Albert et al., 1999) . Such findings have supported the belief that rats and dogs are not predictive of glucuronidation by UGT1A9 substrates, and that monkeys might be a better model for this purpose. However, the present findings with compound 1 suggest that this might not always be the case. Given this unique species selectivity, compound 1 might be a useful probe to investigate such species differences in UGT functionality.
Thirdly, detailed kinetic analysis of N-glucuronide formation can shed further light on the apparent species differences and similarities. M1 formation was biphasic in rat, dog and human liver microsomes indicating that two enzymes, one high affinity and one low affinity, are responsible for M1 formation in these species in vitro ( Figure 5 ). In humans this conclusion is supported by reaction phenotyping experiments, which confirmed that UGT1A1 and UGT1A9 predominantly formed M1 in vitro. If UGT1A1 is assumed to be one of the UGTs responsible for M1 formation in rats and dogs, another UGT, besides UGT1A9, might be implied as the second enzyme, given UGT1A9 activity was found to be lacking in rats and dogs. Since other human UGTs were found to have minor activity in compound 1 N-glucuronidation, perhaps rat or dog orthologs of these UGTs are more important in these species. In monkey liver microsomes, M1 was It is not currently known whether monkey UGT1A1 or UGT1A9 contributed to this
kinetics, or what the specific nature of the mechanism behind the kinetics might be.
Nevertheless this observation supports the uniqueness of monkeys among species in the N-glucuronidation of compound 1. Aside from some clear capacity differences across species, formation of M2 and M3 were more similar across species, following single enzyme kinetics. The finding in human liver microsomes was supported by additional reaction phenotyping experiments, where M2 and M3 were formed principally by a single UGT, UGT1A9. Generally, capacity for compound 1 N-glucuronidation was much higher in human and monkey liver microsomes than in rat or dog liver microsomes, but the metabolic profiles in rats and dogs were qualitatively more similar to that in humans in vitro.
Reaction phenotyping experiments with compound 1 also have potential clinical relevance. Since compound 1 N-glucuronidation occurred predominantly by UGT1A1
and UGT1A9, care must be taken to avoid potential drug interactions with potent inhibitors of these enzymes. However, having more than one UGT responsible, in addition to any oxidation metabolism, may help limit effects of inhibition of any single UGT. In addition, since UGT1A1 is highly expressed in the human intestine (Rowland et al., 2013) , inhibition of UGT1A1, or known polymorphisms, could impact the bioavailability of compound 1, if bioavailability is limited by metabolism by UGT1A1 in the gut. Further in vitro and physiological modeling studies might be warranted to clarify the potential impact of UGT inhibition or polymorphisms.
This article has not been copyedited and formatted. The final version may differ from this version. In summary, compound 1 was shown to undergo extensive N-glucuronidation in BDC rats. N-glucuronides were detected on positions N1 (M2) and N2 (M1) of the pyrazole moiety as well as on the primary amine (M3). All three N-glucuronide metabolites were detected in liver microsomes of the rat, dog and human, while primary amine glucuronidation (M3) was not detected in monkey. In addition N1-and N2-glucuronidation showed strong species selectivity in vitro, with rats, dogs and humans favoring N2-glucuronidation and monkeys favoring N1-glucuronide formation.
Formation of M1 (N2-glucuronidation) in monkey liver microsomes also followed sigmoidal kinetics, singling out monkey as unique among the species as far as compound 1 N-glucuronidation. In this respect, monkey might not always be the best animal model for N-glucuronidation of UGT1A9 or UGT1A1 substrates in humans.
Impact of N-glucuronidation could be more pronounced in higher species such as monkey and human, leading to high clearance in these species. While compound 1 shows promise as a candidate for investigating the impact of pan-mTOR inhibition in vivo, opportunities may exists through medicinal chemistry effort to potentially reduce metabolic liability with the goal of improving systemic exposure.
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